Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Avastin plus chemotherapy shows clinical benefit in breast cancer study
May 19th, 2005
Genentech, Inc., (DNA) and Roche (SWX Zurich) announced that an interim analysis of a phase III study of Avastin (bevacizumab) plus paclitaxel chemotherapy in first-line metastatic breast cancer met its primary efficacy endpoint of showing an improvement in progression-free survival, compared to chemotherapy alone. "This study is very important for two reasons: it demonstrates that Avastin has clinical benefit when used in combination with chemotherapy in first-line metastatic breast cancer and reinforces our belief that targeting angiogenesis can result in patient benefit in multiple tumor types, including colorectal and non-small cell lung cancers," said Hal Barron,...
Source: Women's Health Weekly (2005-05-19)
|
